Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Jacqueline O'brien"'
Autor:
Yoshiya Tanaka, Mitsumasa Kishimoto, Koshiro Sonomoto, Koichi Amano, Masayoshi Harigai, Alina Onofrei, Jacqueline O’Brien, Zachary Margolin, Christine Barr, Yasushi Mizuno, Ekta Agarwal, Naonobu Sugiyama, Hisashi Yamanaka
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1237-1253 (2024)
Abstract Introduction The evolution of disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA) has improved patient prognosis. However, more real-world safety/effectiveness data comparing methotrexate (MTX), tofa
Externí odkaz:
https://doaj.org/article/bd4e692904d347f48204599691f8f2c3
Autor:
Joshua F. Baker, Catherine Bakewell, Ara Dikranian, Gordon Lam, Jacqueline O’Brien, Page C. Moore, Miao Yu, Peter Hur, Karim R. Masri
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 841-853 (2024)
Abstract Introduction Real-world studies describing biosimilar initiation or switching in patients with rheumatoid arthritis (RA) are limited. The aim of this study was to assess treatment patterns and effectiveness of real-world patients with RA ini
Externí odkaz:
https://doaj.org/article/67521a50405f43d9883fc2ca5b204a32
Autor:
Dimitrios A. Pappas, Jacqueline O’Brien, Lin Guo, Ying Shan, Joshua F. Baker, Gregory Kricorian, Scott Stryker, David H. Collier
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-10 (2023)
Abstract Background Real-world studies assessing the comparative effectiveness of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) as first-line targeted therapy are scarce. We analyzed the real-world persistence and
Externí odkaz:
https://doaj.org/article/d0064a88add9404883895a3a6f26b1f8
Autor:
Philip J. Mease, Jacqueline O'Brien, Nicole Middaugh, Gregory Kricorian, Scott Stryker, David H. Collier, Alexis Ogdie
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 8, Pp 388-398 (2023)
Objective Real‐world studies assessing treatment response by psoriatic arthritis (PsA) domains are limited. This study aimed to describe the patient characteristics, frequency and combinations of disease domains, disease activity, and patient‐rep
Externí odkaz:
https://doaj.org/article/e7cde6931ae94e99a1ad7f49603618fd
Autor:
Raymond K. Cross, Jenny S. Sauk, Joe Zhuo, Ryan W. Harrison, Samantha J. Kerti, Kelechi Emeanuru, Jacqueline O’Brien, Harris A. Ahmad, Antoine G. Sreih, Joehl Nguyen, Sara N. Horst, David Hudesman
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 6, Pp 927-935 (2022)
Background and Aims: This study aimed to evaluate associations between disease severity, patient-reported outcomes (PROs), and work productivity in patients with inflammatory bowel disease (IBD [Crohn’s disease (CD) and ulcerative colitis (UC)]). M
Externí odkaz:
https://doaj.org/article/a966b9317578497aac871332a9cb970d
Autor:
Hisashi Yamanaka, Mitsumasa Kishimoto, Nobuo Nishijima, Katsuhisa Yamashita, Junnosuke Matsushima, Jacqueline O’Brien, Taylor Blachley, Melissa Eliot, Zachary Margolin, Swapna S Dave, Yoshiya Tanaka
Publikováno v:
Modern Rheumatology.
Objectives We evaluate the socioeconomic impact of treatment with biological and targeted synthetic disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Methods We analysed data retrospectively from the prospective
Autor:
Laura Carlson, Nitin Gujral, Jacqueline O’Brien, Pedro J. del Nido, Meena Nathan, Vincent W. Chiang
Publikováno v:
Cardiology in the Young. 32:1032-1040
Background:In this era of public scrutiny, there is an ongoing need for innovative methods for patient follow-up.Objectives:As part of a quality initiative, we developed an automated post-operative follow-up system for patients following discharge af
Autor:
Mona Shahriari, Robert R. McLean, Jacqueline O’brien, Elsie L Grace, Russel Burge, Mwangi J Murage, Margaux M. Crabtree, Chen-Yen Lin, Ryan W. Harrison, Orin Goldblum, William N Malatestinic
Publikováno v:
Journal of Dermatological Treatment. 33:1538-1546
There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes.Adult patients with psoriasi
Autor:
Abraham, Betsy, Parent, Dennis, Frey, Sharon, Dagan, Ron, Ashur, Yaffa, Chen, Xiao Q., Ibarra, Jose, Kollaritsch, Herwig, Mazur, Mark H., Poland, Gregory A., Reisinger, Keith, Walter, Emmanuel, Damme, Pierre Van, Braconier, Jean H., Uhnoo, Ingrid, Wahl, Martin, Blatter, Mark M., Clements, Dennis, Greenberg, David, Jacobson, Robert M., Norrby, S. Ragnar, Rowe, Mina, Shouval, Daniel, Simmons, Sue S., Van Hattum, Jan, Wennerholm, Solveig, Gress, Jacqueline O'Brien, Chan, Ivan, Kuter, Barbara
Publikováno v:
The Journal of Infectious Diseases, 2000 Sep 01. 182(3), 1005-1006.
Externí odkaz:
https://www.jstor.org/stable/30109316
Autor:
Frey, Sharon, Dagan, Ron, Ashur, Yaffa, Chen, Xiao Q., Ibarra, Jose, Kollaritsch, Herwig, Mazur, Mark H., Poland, Gregory A., Reisinger, Keith, Walter, Emmanuel, Van Damme, Pierre, Braconier, Jean H., Uhnoo, Ingrid, Wahl, Martin, Blatter, Mark M., Clements, Dennis, Greenberg, David, Jacobson, Robert M., Norrby, S. Ragnar, Rowe, Mina, Shouval, Daniel, Simmons, Sue S., van Hattum, Jan, Wennerholm, Solveig, Gress, Jacqueline O'Brien, Chan, Ivan, Kuter, Barbara
Publikováno v:
The Journal of Infectious Diseases, 1999 Dec 01. 180(6), 2018-2022.
Externí odkaz:
https://www.jstor.org/stable/30109241